Infantile Spasms Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Infantile Spasms Therapeutics Market Analysis

The Infantile Spasms Therapeutics Market size is estimated at USD 206 million in 2024, and is expected to reach USD 269.75 million by 2029, growing at a CAGR of 5.54% during the forecast period (2024-2029).

The growth of the infantile spasms market is influenced by several key factors that underscore its dynamics and evolution, including the rising burden of infantile spasm cases and technological advancements in developing new therapeutics for this disease. Various factors lead to infantile spasms, including infections, brain injury, or arteriovenous malformations. Hence, the growing risk of these factors increases the prevalence of infantile spasms, which will boost the market growth during the forecast period.

For instance, according to the World Health Organization (WHO), in June 2024, quick and adequate identification and treatment of infections in young infants (0-59 days old), especially newborns (0-28 days old), are crucial to ensure their survival and reduce morbidity. In addition, the same source stated that neonatal sepsis significantly contributes to the health challenges faced by low- and middle-income countries like India and African countries. This shows the significantly high burden of neonatal infections among various countries, which can lead to infantile spasms, thereby increasing the usage of therapeutics and boosting market growth during the study period.

Also, the growing awareness through campaigns on infantile spasm disease and its management is expected to propel the market growth over the coming years. For instance, in November 2023, the President of TSC Alliance emphasized that the primary objective of Infantile Spasms Awareness Week (ISAW), observed from December 1 to 7, is to heighten awareness and comprehension of infantile spasms. This is achieved by disseminating educational resources to healthcare providers, caregivers, and the general public. This campaign also prioritizes infantile spasm treatment due to its health emergency. Hence, the awareness campaigns likely drive the market growth during the forecast period.

Therefore, the significant burden of infantile spasms due to various factors and growing awareness of the treatment are expected to drive the market growth during the forecast period. However, the low success rate of treatment and increased risk of side effects and adverse drug effects are expected to hinder the market's growth during the forecast period.

Infantile Spasms Therapeutics Market Trends

Vigabatrin is Expected to Hold a Significant Share in the Market During the Forecast Period

Infantile Spasms Therapeutics Industry Segmentation

As per the scope of the report, infantile spasms, also called West syndrome, is a rare type of epilepsy that typically begins in infancy, usually between 3 and 8 months of age. It is characterized by sudden, jerking movements or spasms of the body, often in clusters. Medications that aim to suppress infantile spasms are considered under infantile spasms therapeutics.

The infantile spasms therapeutics market is segmented into drug type, route of administration, distribution channel, and geography. By drug category, the market is segmented into adrenocorticotropic hormone (ACTH), corticosteroids, and antiepileptic drugs. The antiepileptic drugs include vigabatrin and other antiepileptic drugs. By route of administration, the market is segmented into oral and parenteral. By distribution channels, the market is segmented into offline pharmacies and online pharmacies. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The market sizing and forecasts are based on the value (USD) for each segment.